Chapter 4: Prescribing Controlled Substances Safely: A DEA Requirement 8 CE Hours
By: Humberto Reinoso, Ph.D., FNP-BC, ENP-BC Author Disclosure : Humberto Reinoso and Colibri Healthcare, LLC do not have any actual or potential conflicts of interest in relation to this lesson. Universal Activity Number (UAN) : 0607-0000-23-008-H08-P Target Audience: Pharmacists in a community-based setting. To Obtain Credit: A minimum test score of 75 percent is needed to obtain a credit. Please submit your answers either by mail, fax, or online at EliteLearning.com/Book Questions regarding statements of credit and other customer ser- vice issues should be directed to 1-888-666-9053. This lesson is $79.95. Learning objectives After completing this course, the learner will be able to: Differentiate among substance use disorders and associated concepts, including diversion. Examine the roles of the DEA, FDA, and HHS in scheduling- controlled substances and enforcing controlled substance laws and regulations. a. Controlled substance act. Differentiate the DEA Controlled Substance Schedules and prescribing regulations. a. DEA Controlled Substance Schedules. b. Schedules of a controlled substance (I, II, III, IV, V). Examine medical marijuana legislation. Describe essential considerations when prescribing controlled substances, including regulatory exceptions and clinical concerns. Activity Type : Knowledge-based Initial Release Date : May 1, 2023 Expiration Date : May 1, 2026 Course overview Nurse Practitioners (NPs), Physician Assistants (PAs), Pharmacists, and Dentists care for patients with disorders in many healthcare settings. Individuals may seek care for an acute illness or worsen- ing of a chronic condition. Often, pain is the leading reason for seeking medical care. Appropriate prescribing practices are criti- cal for all medications, but controlled substances require special attention. The Drug Enforcement Agency (DEA), the Food and Drug Administration (FDA), and the U.S. Department of Health and Human Services (HHS) all have a role in controlled medica- tion schedules. Prescribers must understand federal and state re-
Colibri Healthcare, LLC is accredited by the Accredi- tation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Partici- pants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 8 contact hours (0.8 CEU) submit-
ted to CPE Monitor as early as within 10 business days after course completion and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
a. Nurse practitioners prescribing controlled substances: re- quirements. b. Integrative Therapies. Controlled substance prescribing practices. a. Prescription drug monitoring programs (PDMPs). b. Electronic prescribing of controlled substances (EPCS). c. Facsimile and oral prescriptions for Schedule II controlled substances. d. Schedules III-V controlled substance prescribing consider- ations. e. FDA warning for codeine- and hydrocodone-containing cough and cold products. f. Special considerations for nurse practitioners prescribing controlled substances. quirements for all controlled substances. This course will provide a general review of federal and state-controlled substance regu- lations and the prescribing practices for controlled substances. Additionally, substance use disorders are complex phenomena affecting many lives. This course also reviews common substance use disorders, including alcohol, anxiolytics, stimulants, hallucino- gens, and tobacco/vaping. However, the focus is on clinical safety considerations when prescribing non-cancer-related opioid medi- cations for acute/chronic pain in adults.
INTRODUCTION
Substance use disorders are a significant public health problem with a wide range of negative effects on individuals' mental, phys- ical, and social well-being. Mental health problems co-occurring with substance use disorders include depressive, anxiety, and psychotic disorders, as well as organic brain syndromes (Ameri- can Psychiatric Association [APA], 2013). Substance use disorders share many of the same features but differ in pharmacology and associated behaviors that account for the unique effects of each substance (Boland & Verduin, 2022). Alcohol, opioids, central
nervous stimulants, cannabinoids, and tobacco describe the phe- nomenon associated with substance disorders. The hallmark of substance use disorders includes cognitive, behavioral, and physi- ological symptoms of intoxication, withdrawal, and dependence (APA, 2013). Diagnosis is based on pathological patterns of sub- stance use. All substances activate the same brain reward path- way via dopaminergic neurotransmission (Paxos & Teter, 2019).
EliteLearning.com/Pharmacy
Book Code: RPTX3024
Page 44
Powered by FlippingBook